A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis.
Phase of Trial: Phase I/II
Latest Information Update: 08 Feb 2012
At a glance
- Drugs CCX 354 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms CARAT-1
- 09 Nov 2010 Results were reported at the Annual American College of Rheumatology Meeting (ACR), according to a ChemoCentryx media release.
- 19 Jul 2010 Actual end date changed from 30 Mar 2010 to 1 Jul 2010 as reported by ClinicalTrials.gov.
- 30 Mar 2010 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History